Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01753141
Other study ID # R01 MH076629-01A1
Secondary ID
Status Completed
Phase N/A
First received December 17, 2012
Last updated September 25, 2013
Start date January 2008
Est. completion date August 2013

Study information

Verified date September 2013
Source Florida State University
Contact n/a
Is FDA regulated No
Health authority United States: Institutional Review Board
Study type Interventional

Clinical Trial Summary

The Smoking Treatment and Anxiety Management Program (STAMP) is a treatment program focused on helping people manage their anxiety while quitting smoking. The study involves coming in to our clinic for 4 treatment sessions, with follow-ups for up to 2 years (a week 1, week 2, month 1, month 3, month 6, year 1, and year 2 follow-up). Participants will be paid $142.50 for their full participation as well as receive 6 weeks of free nicotine replacement patches.


Recruitment information / eligibility

Status Completed
Enrollment 378
Est. completion date August 2013
Est. primary completion date August 2013
Accepts healthy volunteers No
Gender Both
Age group 18 Years to 45 Years
Eligibility Inclusion Criteria:

- Anxiety Sensitivity Index greater than 15

- Daily smoker for at least 1 year

- Less than 45 years old

- Currently smoke at least 8 cigarettes per day

- Report a motivation to quit smoking

Exclusion Criteria:

- History of panic disorder

- Psychotropic medication use (if not stable for 3 months)

- History of significant medical condition

- Current use of smoking cessation pharmacology

- Use of other tobacco products

- Planning to move in the next 6 months

Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment


Related Conditions & MeSH terms


Intervention

Behavioral:
Cognitive Behavioral Therapy for smoking cessation

Cognitive Behavioral Therapy for smoking cessation and anxiety sensitivity reduction.
Includes anxiety sensitivity (AS) psychoeducation and interoceptive exposure exercises in addition to regular smoking cognitive behavioral therapy.

Locations

Country Name City State
United States Anxiety and Behavioral Health Clinic Tallahassee Florida

Sponsors (1)

Lead Sponsor Collaborator
Florida State University

Country where clinical trial is conducted

United States, 

References & Publications (8)

Brandt CP, Johnson KA, Schmidt NB, Zvolensky MJ. Main and interactive effects of emotion dysregulation and breath-holding duration in relation to panic-relevant fear and expectancies about anxiety-related sensations among adult daily smokers. J Anxiety Di — View Citation

Buckner JD, Joiner TE Jr, Schmidt NB, Zvolensky MJ. Daily marijuana use and suicidality: the unique impact of social anxiety. Addict Behav. 2012 Apr;37(4):387-92. doi: 10.1016/j.addbeh.2011.11.019. Epub 2011 Nov 25. — View Citation

Buckner JD, Zvolensky MJ, Schmidt NB. Cannabis-related impairment and social anxiety: the roles of gender and cannabis use motives. Addict Behav. 2012 Nov;37(11):1294-7. doi: 10.1016/j.addbeh.2012.06.013. Epub 2012 Jun 22. — View Citation

Capron DW, Blumenthal H, Medley AN, Lewis S, Feldner MT, Zvolensky MJ, Schmidt NB. Anxiety sensitivity cognitive concerns predict suicidality among smokers. J Affect Disord. 2012 May;138(3):239-46. doi: 10.1016/j.jad.2012.01.048. Epub 2012 Feb 26. — View Citation

Funk, A. P., Zvolensky, M. J., & Schmidt, N. B. Homework compliance in a brief cognitive-behavioral and pharmacological intervention for smoking. Journal of Smoking Cessation (6): 99-111, 2011.

Johnson KA, Farris SG, Schmidt NB, Zvolensky MJ. Anxiety sensitivity and cognitive-based smoking processes: testing the mediating role of emotion dysregulation among treatment-seeking daily smokers. J Addict Dis. 2012;31(2):143-57. doi: 10.1080/10550887.2 — View Citation

Leventhal AM, Zvolensky MJ, Schmidt NB. Smoking-related correlates of depressive symptom dimensions in treatment-seeking smokers. Nicotine Tob Res. 2011 Aug;13(8):668-76. doi: 10.1093/ntr/ntr056. Epub 2011 Apr 6. — View Citation

Peasley-Miklus CE, McLeish AC, Schmidt NB, Zvolensky MJ. An examination of smoking outcome expectancies, smoking motives and trait worry in a sample of treatment-seeking smokers. Addict Behav. 2012 Apr;37(4):407-13. doi: 10.1016/j.addbeh.2011.11.037. Epub — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Anxiety Sensitivity Index The ASI is a 16-item self-report measure that assesses the fear of consequences of bodily sensations associated with anxiety. Items are rated on a five-point Likert-type scale ranging from 0 (very little) to 4 (very much) and a total score is computed by summing all items. The ASI is hierarchical in structure with one higher order factor (AS) and three subfactors (physical, cognitive, and social concerns). The physical concerns subscale includes items related to the fear of consequences or presence of specific physical sensations (e.g. "When I notice that my heart is beating rapidly, I worry that I might have a heart attack"). The cognitive concerns subscale includes items related to potential mental health implications of sensations (e.g. "When I cannot keep my mind on a task, I worry that I might be going crazy"). The social concerns subscale includes items related to the potential social consequences of physical sensations (e.g. "It is important to me not to appear nervous"). up to 2 years No
Secondary Smoking Status week 1, week 2, month 1, month 3, month 6, year 1, and year 2 follow-up No
See also
  Status Clinical Trial Phase
Recruiting NCT05176418 - IV Pulsed-Nicotine as a Model of Smoking: The Effects of Dose and Delivery Rate Early Phase 1
Completed NCT04084210 - Impact of Alternative Nicotine-Delivery Products on Combustible Cigarette Use Phase 2
Completed NCT04043728 - Addressing Psychological Risk Factors Underlying Smoking Persistence in COPD Patients: The Fresh Start Study N/A
Withdrawn NCT03707600 - State and Trait Mediated Response to TMS in Substance Use Disorder N/A
Recruiting NCT03999099 - Targeting Orexin to Treat Nicotine Dependence Phase 1
Completed NCT03847155 - Prevention of Nicotine Abstinence in Critically Ill Patients After Major Surgery N/A
Completed NCT02840435 - Study on Sit to Quit Phone Intervention N/A
Completed NCT02139930 - Project 2: Strategies for Reducing Nicotine Content in Cigarettes N/A
Completed NCT01982110 - A Mindfulness Based Application for Smoking Cessation N/A
Completed NCT01926626 - Evaluation of Moclobemide, a Reversible MAO-A Inhibitor, as an Adjunct to Nicotine Replacement Therapy in Female Smokers Phase 2
Withdrawn NCT01569477 - Striving to Quit-Wisconsin Tobacco Quit Line N/A
Completed NCT01685996 - Zonisamide Augmentation of Varenicline Treatment for Smoking Cessation Phase 1/Phase 2
Completed NCT01632189 - The Effect of Varenicline on D2/D3 Receptor Binding in Smokers N/A
Completed NCT01569490 - Striving to Quit: First Breath N/A
Active, not recruiting NCT01182766 - New Treatment for Alcohol and Nicotine Dependence Phase 2/Phase 3
Completed NCT01061528 - Coping Skills Treatment for Smoking Cessation N/A
Completed NCT00996034 - Nicotine Vaccination and Nicotinic Receptor Occupancy Phase 2
Withdrawn NCT01589081 - Effects of Progesterone on IV Nicotine-Induced Changes in Hormones and Subjective Ratings of Stimulant Drug Effect N/A
Suspended NCT01636336 - Effects of Progesterone on Smoked Nicotine Induced Changes in Hormones and Subjective Ratings of Stimulant Drug Effects N/A
Completed NCT01943994 - Psilocybin-facilitated Smoking Cessation Treatment: A Pilot Study N/A